C. difficile control set, 10/14
October 2014—SeraCare Life Sciences announced the launch of its Accurun 501 C. difficile Control, the company’s first molecular control product targeting hospital-acquired infections.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Pneumococcal array, 10/14
October 2014—Quansys Biosciences is releasing Q-Plex Pneumococcal Array (14-plex) for the evaluation and detection of IgG antibody concentrations to pneumococcal polysaccharide serotypes 1, 3, 4, 6B, 7F, 8, 9N, 9V, 12F, 14, a8C, 19A, 19F, and 23F.
Private equity firm purchases Cole-Parmer, 10/14
October 2014—Thermo Fisher Scientific announced it has completed the sale of its Cole-Parmer customer channel business to private equity firm GTCR for approximately $480 million in cash.
FDA-approved molecular assay for blood transfusions, 9/14
September 2014—Immucor’s PreciseType HEA test is an FDA-approved molecular assay designed to provide clinicians and blood banks with the detailed genetic matching information they need to reduce the risk of alloimmunization and serious hemolytic reactions, which is especially problematic for patients receiving frequent blood transfusions.
Tissue, chromatography, and high-recovery vials, 9/14
September 2014—Wheaton’s CryoElite Tissue Vials are designed for the safe, secure, and effective cryopreservation of biological tissue specimens and are able to maintain sample integrity while maximizing storage capacity and organization. CryoElite Tissue Vials were developed for the high-performance tissue banking requirements of anatomical pathology departments, clinical trial organizations, and biorepository and biobanking facilities.
High-speed sorters, 9/14
September 2014—AutoSorter 2000BB is Yaskawa Motoman’s new high-speed bulk sorter for high-volume commercial laboratories. AutoSorter 2000BB provides specimen throughput of up to 2,000 tubes per hour. It minimizes manual handling of specimens through bulk loading and unloading, and reduces sequential sorting by fine sorting in one step.
Gold nanoshells, 9/14
September 2014—NanoComposix unveiled its BioReady Gold line of products that include new surface chemistries for covalent attachment to gold nanoparticles and gold nanoshells.
Automated molecular diagnostics technology, 9/14
September 2014—Rheonix displayed its Chemical and Reagent Device, CARD, and EncompassMDx molecular testing platform at AACC. The Rheonix CARD is a disposable cartridge the size of a credit card that runs multiple samples simultaneously without user intervention.
Roche products and acquisitions, 9/14
September 2014—New products featured by Roche this year include analyzers, an automated workflow series, and assays. The Cobas u 601 urine analyzer is a fully automated solution for urine strip testing in mid- to high-volume labs that delivers high-quality results through reagent test strips. This analyzer is not available for sale in the U.S.; a 510(k) submission is pending.
Integrated diagnostic solutions, 9/14
September 2014—Currently in development from Abbott is the Iridica platform, targeted for release in CE-marked European countries within 12 months, to test for and identify hundreds of bacteria and candida, fungi, and viruses from a direct patient specimen.